Protein Binding of Lopinavir and Ritonavir During 4 Phases of Pregnancy: Implications for Treatment Guidelines by Patterson, Kristine B. et al.
Protein Binding of Lopinavir and Ritonavir During Four Phases
of Pregnancy: Implications for Treatment Guidelines
Kristine B. Patterson, MD1, Julie B. Dumond, PharmD, MS2, Heather A. Prince, PA-C1,
Amanda J. Jenkins, PharmD2,*, Kimberly K. Scarsi, PharmD3, Ruili Wang, MD2, Stephanie
Malone, MS2, Michael G. Hudgens, PhD1, and Angela DM. Kashuba, PharmD2
1University of North Carolina Department of Medicine, Chapel Hill, NC
2University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC
3Northwestern University Feinberg School of Medicine, Chicago, IL
Abstract
Objective—To investigate the intraindividual pharmacokinetics of total (protein bound +
unbound) and unbound lopinavir/ritonavir (LPV/RTV) and to assess whether the pediatric
formulation (100mg/25mg) can overcome any pregnancy-associated changes.
Design—Prospective longitudinal pharmacokinetic (PK) study
Methods—HIV-infected pregnant antiretroviral therapy-naïve and experienced women receiving
LPV/RTV 400mg/100mg tablets twice daily. Intensive PK evaluations were performed at 20–24
weeks (PK1), 30 weeks (PK2) followed by empiric dose increase using the pediatric formulation
(100mg/25mg twice daily), 32 weeks (PK3), and 8 weeks postpartum (PK4).
Results—Twelve women completed pre-specified PK evaluations. Median (range) age was 28
(1–35) years and baseline BMI was 32 (19–41) kg/m2. During pregnancy, total area under the time
concentration (AUC0–12hr) for LPV was significantly lower than postpartum [PK1, PK2 or PK3
vs. PK4, p= 0.005]. Protein unbound LPV AUC0–12hr remained unchanged during pregnancy
[PK1: 1.6 (1.3–1.9) vs. PK2: 1.6 (1.3–1.9) µg*hr/mL, p=0.4] despite a 25% dose increase [PK2 vs.
PK3: 1.8 (1.3–2.1) µg*hr/mL, p=0.5]. Protein unbound LPV predose concentrations (C12h) did not
significantly change despite dose increase [PK2: 0.10 (0.08–0.15) vs. PK3: 0.12 (0.10–0.15) µg/
mL, p=0.09]. Albumin and LPV AUC0–12h fraction unbound were correlated (rs=0.3, p=0.03).
Conclusions—Total LPV exposure was significantly decreased throughout pregnancy despite
the increased dose. However, the exposure of unbound LPV did not change significantly
regardless of trimester or dose. Predose concentrations of unbound LPV were not affected by the
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additional dose and were 70-fold greater than the minimum efficacy concentration. These findings
suggest dose adjustments may not be necessary in all HIV-infected pregnant women.
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Background
HIV-infected pregnant women receive antiretroviral therapy for their own health and to
prevent mother-to-child transmission of HIV. The US Department of Health and Human
Services (DHHS) guidelines have recommended lopinavir/ritonavir (LPV/RTV, Kaletra®)
as the first-line protease inhibitor for either goal (1). It has been previously demonstrated
that standard dosing (400mg/100mg) using three LPV/RTV soft-gel capsules twice daily
results in third trimester lopinavir area under the concentration-time curve (AUC) and
trough concentrations below a target of 52ug*hr/mL and 1 µg /mL, respectively (2–5). This
decrease in exposure was not overcome with dose increases to 533mg/133 mg (four
capsules) twice daily (6). Exposure between the new Meltrex® tablet (200mg/50mg)
formulation and standard-dose LPV/RTV soft-gel capsules are not significantly different,
though over 17% of women receiving either formulation have lopinavir trough
concentrations below 3 µg/mL (7). Dose increases to 600mg/150mg twice-daily results in
third trimester concentrations similar to nonpregnant exposures at the standard 400mg/
100mg dose (8). Based on these data, DHHS guidelines recommends increasing LPV/RTV
dose to 600mg/150 mg twice daily in the third trimester. However, the increased
bioavailability of the tablet formulation has the potential to decrease tolerability and increase
toxicity at this higher dose.
Lopinavir and ritonavir are 98–99% bound to the blood plasma proteins albumin and
alpha-1-acid-glycoprotein (AAG), and only protein-unbound drugs are available to traverse
cell membranes and exert a pharmacologic effect (9). Due to technical complexity and the
requirement for advanced analytical instrumentation, pharmacokinetic studies generally
measure total drug concentrations (protein bound plus unbound) rather than unbound drug.
Additionally, since plasma protein binding in most populations is consistent, measuring
unbound drug is often unnecessary to assess efficacy(10). Pregnancy, however, is associated
with alterations in plasma proteins (11–13), which may affect unbound drug concentrations.
Consequently, total lopinavir and ritonavir exposures may not reflect drug available for
antiviral activity; in this situation, protein unbound drug concentrations may be most
relevant.
Few studies have longitudinally and comprehensively measured unbound lopinavir and
ritonavir concentrations throughout pregnancy. Investigations with sparse sampling have
had mixed results: either an 18% increase in the fraction of unbound lopinavir in third
trimester compared with postpartum (14), or no significant changes (15).
To address the hypothesis that the physiological changes associated with pregnancy will
decrease the total (protein bound plus unbound) but not the protein-unbound (active)
lopinavir and ritonavir concentrations, this study longitudinally evaluates total and unbound
lopinavir and ritonavir exposures in HIV-infected pregnant women in the second and third
trimesters of pregnancy and postpartum. The pediatric formulation of LPV/RTV (100mg/
25mg twice daily), rather than an additional adult tablet (200mg/50mg), is empirically added
to standard dosing (400mg/100mg twice daily) in the third trimester. The study is designed
to investigate whether LPV/RTV 500mg/125mg is able to overcome any pregnancy-
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associated changes in total and free drug exposure while minimizing toxicity and
maximizing tolerability.
Methods
Study Design and Subject Selection
HIV-infected pregnant women were enrolled in this open-label, longitudinal
pharmacokinetic (PK) study to assess the total (protein-bound plus unbound) and protein-
unbound exposure of fixed-dose combination lopinavir/ritonavir tablets (LPV/RTV,
Kaletra®, Abbott Laboratories, Abbott, IL USA). Subjects were recruited from the
Infectious Diseases Clinics at the University of North Carolina (UNC) at Chapel Hill, North
Carolina and Northwestern University (NU), Chicago, Illinois. The Biomedical Review
Boards from each individual institution approved the study, and all subjects provided written
informed consent prior to study procedures. Subjects were enrolled from October 2007 to
September 2009 (National Clinical Trial Registry No. 00766818).
Subjects were eligible to participate if they were less than 20 weeks gestation and receiving
or planning to initiate LPV/RTV tablets (400 mg/100 mg twice daily). Subjects were
required to be ≥18 years of age with a current singleton and uncomplicated pregnancy.
Subjects were excluded if they were being treated for an opportunistic infection; had prior
obstetrical complications or preterm delivery; had a hemoglobin < 9.0 gm/dL; were unable
to complete a dose record card at home; were <80% adherent to the current antiretroviral
regimen as determined by dosing card, provider or self report; or were receiving other
protease inhibitors or concurrent medications known to interact with LPV/RTV. Subjects
with documented virologic failure of a LPV/RTV regimen or who had a genotype that
would predict failure to LPV/RTV were excluded.
Two to four weeks prior to enrollment, subjects underwent screening in which informed
consent, physical examination and routine safety laboratory testing (complete blood count,
serum chemistries, liver function tests, urinalysis, and absolute CD4+ cell count and HIV
RNA) were performed, and medical and obstetrical histories were obtained. Subjects agreed
to allow investigators to capture any laboratory results, clinical events or sonograph results
that occurred between study visits. HIV DNA results for the infants were obtained at 0–2
days, 2–4 weeks, 4–6 weeks and 4–6 months of life as part of routine infant care. All infants
received oral zidovudine 2mg/kg every 6 hours for 6 weeks postpartum in addition to
intravenous zidovudine at delivery.
Study Visits
Subjects underwent four intensive pharmacokinetic (PK) visits with observed dosing within
15 minutes of a standard meal in the clinical research units at the following time points: 20–
24 weeks (PK1), 30 weeks (PK2), 32 weeks (PK3) gestation, and 8 weeks post partum
(PK4). Subjects were contacted one week prior to each PK visit to reinforce compliance, to
record the time of each dose on provided cards, and to bring cards to study visit. Adherence
was also assessed by pill counts at each study visit. Safety labs (hemoglobin, chemistries)
were obtained at all visits before blood samples for PK analysis were initiated. At each PK
visit, blood samples were obtained 30 minutes prior to dosing and 2, 4, 6, 8, 10 and 12 hours
postdose. The LPV/RTV dose was 400mg/100mg twice daily at PK1 and PK2. Immediately
following completion of PK2, the dose was increased to 500/125mg twice daily by adding a
100mg/25 mg tablet (pediatric formulation) to standard-dose in order to determine possible
effects on drug exposure using a smaller dose as an alternate dosing strategy. PK 3 occurred
two weeks later. The 500mg/125mg dose was continued for the remainder of pregnancy
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through 2 weeks postpartum, at which time the dose was decreased to 400mg/100mg twice
daily for the duration of the study.
Sample Processing
Whole blood was obtained using K2-EDTA-containing collection tubes (Becton Dickinson,
Franklin Lakes, NJ) and centrifuged at 3000g for 15 minutes at 4°C within 30 minutes of
collection. The resulting plasma was divided into labeled cryovials and stored at −80°C until
analysis. Total drug concentrations in plasma for lopinavir and ritonavir were measured
using validated and Division of AIDS CPQA-approved high performance liquid
chromatography (HPLC) method with ultraviolet detection. Intraday and interday variability
was <10% and the dynamic range was 10–10,000 ng/mL (16).
Protein binding quantification was performed by rapid equilibrium dialysis as previously
described (17). Briefly, plasma was incubated at 37°C for 18 hours in rapid equilibrium
dialysis cartridges (Thermo Scientific, Pittsburg, PA) followed by liquid-liquid extraction
with methyl tert-butyl ether (MTBE) (Fisher Scientific, Norcross, GA, USA). Darunavir (in
50/50 methanol: water) was used as the internal standard. An Agilent 1200 series HPLC
System and an Agilent 1100 MSD (Agilent Technologies, New Castle, DE) in positive ESI
mode were used. Analytes were separated on an Agilent Zorbax Eclipse XDB-C8 (3.0 ×
50mm, 1.8m) column. For both lopinavir and ritonavir, assay sensitivity was 2 ng/ml,
precision was within 15%, and accuracy was 95–110% for lopinavir and 90–107% for
ritonavir. Recovery for both drugs was >90%.
Statistical Analyses
Pharmacokinetic parameters were estimated using noncompartmental methods (Phoenix
WinNonlin Pro 5.2; Certara, L.P., St. Louis MO). Maximum concentration (Cmax), time at
maximum concentration (Tmax), and concentration 12 hours after dosing (C12h) were
determined by visual inspection of the subject profiles, and used the log-linear trapezoidal
method to calculate the area-under-the-time-concentration-curve over the 12-hour dosing
interval (AUC0–12h). Total drug apparent oral clearance was calculated as dose/AUC0–12h.
Detectable concentrations that were below the limit of quantification were imputed as 50%
of the lower limit of quantification. Descriptive statistics using Phoenix WinNonlin Pro 5.2
were performed. Pharmacokinetic parameters are presented in median (interquartile range
(IQR)) unless otherwise noted. Differences in pharmacokinetic parameters at different time
points were assessed using the Wilcoxon signed rank test. No adjustments were made for
multiple comparisons.
The percent protein unbound of lopinavir was calculated by subtracting percent protein
bound from 100%. Correlation between albumin or α-1-acid glycoprotein (AAG) and
unbound drug concentrations were assessed using Spearman rank correlation coefficients.
Results
Patient Characteristics
Twelve HIV-infected pregnant women from two academic institutions (11 UNC, 1 NU)
were enrolled, and all completed the study as designed. Demographic information is
presented in Table 1. The median age of the participants was 28 (range 18–35) years;
median body mass index (BMI) was 32 (range 19–41) kg/m2 at enrollment. Nine (75%)
were Black. Eight subjects were antiretroviral naïve and initiated therapy at a median of 12
(7–18) weeks gestation, consisting of lopinavir/ritonavir 400mg/100mg (LPV/RTV) twice
daily in addition to the nucleoside reverse transcriptase inhibitor (NRTI) fixed-dose
combinations of either zidovudine 300mg/lamivudine 150mg (ZDV/3TC) twice daily or
Patterson et al. Page 4













tenofovir disoproxil fumarate 300mg/emtricitabine 200mg (TDF/FTC) once daily. The
remaining 4 subjects had received 1 or 2 prior antiretroviral regimens. One subject was on
ZDV/3TC plus an unboosted protease inhibitor prior to pregnancy and was switched to
LPV/RTV after pregnancy was confirmed; and the other three were not on antiretroviral
therapy and initiated LPV/RTV (plus ZDV/3TC or TDF/FTC) after 12-weeks gestation for
fetal protection.
Study enrollment occurred between 16–20 weeks gestation. At enrollment, eleven (92%)
subjects were receiving ZDV/3TC and one (8%) TDF/FTC. One subject developed
hemolytic anemia at 24 weeks gestation, which had occurred in a pregnancy 12 years prior
when the subject was HIV-negative. As a result, ZDV/3TC was discontinued and the subject
was changed to TDF/FTC for the remainder of the pregnancy. Therefore, two subjects
received TDF/FTC for the majority of gestation. The median absolute CD4 count was 509
(116–880) cells/mm3 at 20–24 weeks. HIV RNA was < 48 copies/mL in all 12 women at
delivery. There were no perinatal transmissions.
Pharmacokinetic (PK) Results
Lopinavir Exposure
Total lopinavir: Total lopinavir AUC0–12h did not change between the second and third
trimesters (PK1 vs. PK2, p=0.58) (Figure 1a). The increased dose also did not result in a
significant difference in total lopinavir AUC0–12h [PK2: median (IQR) 64.1 (51.3–69.7) vs.
PK3: 69.1 (55.2–78.2) µg*hr/mL; p=0.27] (Table 2). Despite a 25% increase in dose, total
lopinavir AUC0–12h increased by only 8% (p=0.37). The median total lopinavir AUC0–12h,
regardless of dose or gestation, was significantly lower than postpartum (PK1, PK2 or PK3
vs. PK4, p=0.005). The apparent oral clearance of lopinavir was significantly higher during
pregnancy than post-partum: 3.1 (2.2–4.2) L/hr in the second trimester, 3.4 (3.1–4.2) in the
third trimester, 3.6 (3.1–3.9) L/hr following the dose increase, and 1.3 (0.6–1.8) L/hr,
postpartum, (PK1, PK2, or PK3 vs. PK4, respectively; p < 0.03).
The greatest changes in lopinavir C12h were between the third trimester (PK2) and
postpartum (PK 4) [4.0 (3.4–5.4) vs. 7.2 (6.1–9.3) µg/mL; p=0.001] (Figure 2A). Postpartum
C12h was 38–80% higher than at any point during pregnancy. The increased dose increase to
500mg/125mg resulted in a 23% increase (4.0 vs. 4.9 µg/mL; p=0.03) in total lopinavir C12h
as measured at 30 and 32 weeks, respectively.
Protein unbound lopinavir: Figure 1b highlights that neither dose nor gestation had an
effect on unbound lopinavir median AUC0–12h.. Table 2 more specifically outlines that lack
of significant changes in median unbound lopinavir AUC0–12h following the increased dose
(PK2 vs. PK3, 1.6 (1.3–1.9) vs. 1.8 (IQR 1.3–2.1) µg*hr/mL, respectively; p=0.47).
Similarly, gestation period did not significantly alter unbound lopinavir exposure before the
dose increase (PK1 vs. PK2; p=0.41), or following the dose increase (PK1 vs. PK3; p=0.76).
Compared to the postpartum AUC0–12h, unbound lopinavir exposure was significantly lower
throughout pregnancy regardless of dose (PK1, PK2 or PK3 vs. PK4, p=0.05, p=0.01, and
p=0.03, respectively).
The increased dose also did not significantly alter the median unbound lopinavir C12h
concentration: (PK3 vs. PK2: 0.12 (0.10–0.15) vs. 0.10 (0.08–0.15) µg/mL, respectively;
p=0.09) (Figure 2b). Unbound lopinavir C12h concentrations were highest in the second
trimester [PK1: 0.15 (0.08–0.16) µg/mL], and did not significantly change following
delivery [0.16 (0.14–0.27) µg/mL; p=0.09)]. Only the C12h at 30 weeks gestation prior to
dose escalation (PK2) was significantly different from the postpartum C12h [PK2: 0.10
(0.08–0.15) vs. PK4: 0.16 (0.14–0.27) µg/mL; p=0.05)]. Less than 2% of all concentrations
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were below the wild type IC50 (50% inhibitory concentration) for unbound lopinavir of
0.00064 µg /mL(18).
Ritonavir Exposure
Total ritonavir: Total ritonavir median AUC0–12h was lower throughout pregnancy,
regardless of dose increase, compared to postpartum AUC0–12h (Figure 1c). The median
total ritonavir AUC0–12h in the second trimester (PK1), the third trimester (PK2) and
following the dose increase (PK3) were 2.5 (1.7–3.0), 2.3 (1.7–3.0), and 2.4 (1.9–3.3) µg*hr/
mL, respectively, compared with 5.2 (2.9–5.8) µg*hr/mL postpartum (PK4); (p=0.002,
p=0.002 and p=0.002, respectively). Overall, total ritonavir exposure was not significantly
changed during pregnancy. Apparent oral clearance of ritonavir (Table 2) was greater during
pregnancy than the postpartum period; (PK1, PK2, or PK3 vs. PK4, p< 0.01).
Total ritonavir C12h were similar between the second and third trimesters [0.12 (0.09–0.20)
vs. 0.12 (0.08–0.14) µg /mL, respectively; p=0.5] (Figure 2c). The higher dose did result in a
significant increase in median C12h to 0.15 (0.11–0.18) µg /mL, p=0.02. Total ritonavir C12h
was significantly lower during pregnancy, despite the additional dose, compared to
postpartum C12h [0.28 (0.2–0.4) µg /mL; (PK1, PK2, or PK3 vs. PK4, p≤0.01].
Protein unbound ritonavir: Similar to lopinavir, the protein unbound ritonavir median
AUC0–12h did not change regardless of gestation or dose (Figure 1d). The dose increase,
(PK2 vs. PK3, 0.3 vs. 0.3 µg*hr/mL, p=1.0) did not alter the unbound ritonavir exposure.
Nor was there a difference in exposure in the second or third trimesters before (PK1 vs.
PK2, p=0.12), or after (PK1 vs. PK3, p=0.97) the dose increase. Postpartum exposure was
significantly higher than during pregnancy regardless of dose (PK1, PK2 or PK3 vs. PK4,
p=0.01, p=0.01, and p=0.03, respectively).
The increased dose did not significantly alter the median unbound ritonavir C12h (PK3 vs.
PK2, p=1.0). The unbound ritonavir C12h was highest in the second trimester (PK1) (0.02
µg/mL) and was the only time in which a significant difference in postpartum C12h was
found (0.02 vs. 0.03 µg/mL, p=0.01).
Less than 1% of all unbound ritonavir concentrations were under 1 mg/mL. A single subject
had concentrations below this threshold at the beginning of her postpartum visit, suggesting
a missed dose or a delay in dosage.
Serum Proteins: The median (IQR) albumin and AAG are shown in Table 1. There were no
significant changes in albumin between the first 3 PK evaluations (PK1 vs. PK2: p=0.2; PK1
vs. PK3: p=0.8, PK2 vs. PK3: p=0.9). There were also no significant changes in AAG (PK1
vs. PK2: p=0.4; PK1 vs. PK3: p=0.2, PK2 vs. PK3: p=0.5). Both albumin and AAG were
significantly greater at postpartum PK4 (p<0.001). The drug binding proteins albumin and
AAG were modestly correlated (rs=0.48, p=0.0006), as were the pharmacokinetic
parameters LPV AUC0–12h and C12h (rs=0.47, p=0.0009). However, in this dataset, only
albumin significantly correlated with LPV AUC0–12h fraction unbound (rs=0.3, p=0.03).
Safety
The additional 100mg/25mg LPV/RTV tablet was tolerated without any complaints of
nausea or vomiting. There were no symptomatic or biochemical adverse events above Grade
1 that were related to LPV/RTV. No subject required premature discontinuation or dosing
alterations.
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The widespread use of antiretroviral therapy has resulted in reduction of perinatal HIV
transmission rates to <1–2% in developed countries (19). However, the pregnancy-
associated variations in drug binding proteins may alter antiretroviral bioactivity (20, 21),
resulting in decreased efficacy, suboptimal maternal viral suppression, and ultimately
perinatal transmission. Conversely, overdosing unnecessarily may increase maternal and
fetal toxicity (22). Because of such risks, understanding the pharmacokinetics of LPV/RTV
is paramount to provide dosing guidance for LPV/RTV in HIV-infected pregnant women.
Unlike previous evaluations (5, 6, 8, 23, 24), this study employed a unique design in which
comprehensive pharmacokinetic measurements of both total (protein bound and unbound)
and protein unbound lopinavir and ritonavir were performed in the same 12 women at
predetermined gestational ages. The intra-subject comparison strategy has not been
previously employed, but is essential in assessing the impact of dose escalation on both the
total drug and protein unbound drug concentrations. Moreover, intensive pharmacokinetic
assessments were performed before and after a 100mg/25mg (or 25% of standard dosing)
pediatric tablet was empirically added to standard dosing (400mg/100mg) as alternative to
“recommended” third trimester dose increases (600mg/150mg or 50% dose increase). Our a
priori hypothesis was that dose increases were not necessary as protein unbound (or active)
drug concentrations were not expected to significantly change despite previously reported
changes in total drug concentrations (3, 5, 6, 8, 15). The ability to assess tolerability and
potential toxicity of a 25% rather than a 50% dose increase would provide clinically useful
information as an alternate strategy for women who may require a dose adjustment. Two
weeks post-partum all women return to standard 400mg/100mg dosing. Pharmacokinetics
were subsequently performed 8 weeks postpartum consistent with normalization of plasma
concentrations in other studies (15), although the precise timing of normalization of
pregnancy-related changes has not been determined. These factors provide the most
comprehensive pharmacokinetic analysis of LPV/RTV in HIV-infected pregnant women to
date.
Our study found that a 25% increase in LPV/RTV dose results in <10% increase in total
lopinavir exposure, which is not clinically relevant as concentrations remain above the
minimum effective concentration (1 µg/mL for wild-type virus) (25). One explanation for
the decrease total lopinavir concentrations is an increase in total lopinavir clearance. Our
estimate of lopinavir clearance during pregnancy is between 120–216% higher than
postpartum estimates, potentially due to changes in enzymatic processes (26). The relative
consistency of Cmax would suggest that oral absorption remains stable.
Higher total lopinavir C12h (4 µg/mL) (27, 28) are targeted in protease inhibitor treatment-
experienced patients. Of the 12 participants in this study, standard-dose LPV/RTV results in
total lopinavir C12h below this threshold in 33% (n=4) of women in the second trimester and
50% (n=6) in the third trimester. Following the dose increase, 91% (n=11) of women
achieve C12h above 4 µg/mL with C12h of 2.9 µg/mL in a single naïve subject. All
participants remain virologically suppressed before and after dose changes despite the
decrease in C12h. However, our study population, by circumstance, had received two or less
prior regimens. Our study suggests that evaluating C12h in the later part of the second
trimester may be beneficial in women who are treatment-experienced to determine whether
pre-dose concentrations are below target and therefore require a dose increase. This strategy
would diminish the risk of potential toxicities when a dose increase is not necessary. The use
of the pediatric formulation (100mg/25mg) provides an alternative dosing strategy when the
C12h falls slightly below the targeted threshold, further minimizing the risk of toxicities.
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The pharmacological effects of LPV/RTV are determined by the protein-unbound (or active)
drug concentration, as only the unbound drug is able to transverse biological membranes and
exert antiviral activity. In contrast to previous investigations, full pharmacokinetic profiles
of unbound lopinavir and ritonavir were generated with our methodology. Using a protein-
unbound IC50 (50% inhibitory concentration) for lopinavir of 0.00064–0.00077 µg/mL (18),
unbound C12h exposures in all women were greater than 70-fold this threshold in the third
trimester prior to the dose increase. The increased dose resulted in <15% increase in protein-
unbound AUC0–12h and <12% increase in C12h. The unbound fraction of lopinavir did not
significantly change during the second or third trimesters and postpartum regardless of dose,
and AUC0–12h modestly correlated with physiological changes in albumin. The addition of a
standard LPV/RTV tablet (200mg/50mg) could possibly have resulted in higher protein-
unbound C12h, which may have been unlikely to benefit our study participants and could
have resulted in toxicity or intolerability.
In conclusion, this study demonstrates the pharmacokinetic effects of pregnancy on total and
unbound lopinavir and ritonavir concentrations before and after empiric dose escalation. For
many pregnant women, especially treatment naïve or women with wild type virus, LPV/
RTV dose increases during pregnancy may not be necessary since the protein-unbound drug
exposure is not altered. If drug exposure in women with resistance mutations is of concern, a
dose increase of 100mg/25mg could be utilized in order to minimize toxicity. Future studies
aimed towards providing accurate dosing recommendations in pregnancy of any
antiretroviral agent will be best achieved through a longitudinal evaluation of total and
unbound drug exposures throughout pregnancy in the same women.
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Figure 1. Concentration-Time Profiles of Lopinavir (LPV) and Ritonavir (RTV)
a. Total (Protein Bound and Unbound) Lopinavir Concentrations
b. Protein Unbound Lopinavir Concentrations
c. Total (Protein Bound and Unbound) Ritonavir Concentrations
d. Protein Unbound Ritonavir Concentrations
Data are presented as median (25th, 75th percentile) (ug/mL)
Reference lines indicate minimal efficacy concentrations.
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Figure 2. Lopinavir and Ritoniavir C12h Comparisons
a. Total (Protein Bound and Unbound) Lopinavir C12h
b. Protein Unbound Lopinavir C12h
c. Total (Protein Bound and Unbound) Ritonavir C12h
d. Protein Unbound Lopinavir C12h
C12h: concentration 12 hours after dosing
Data are reported as median (25th, 75th percentile) (µg/mL)
(Only statistically significant differences are identified)
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